ArticleADMET & DMPK2026
Bimetallic metal organic framework modified screen printed electrode for simultaneous voltammetric determination of calcium folinate and methotrexate.
Article in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Calcium folinate (CFT) is a medication used as an antidote to methotrexate (MTT) and as a vitamin against anaemia. MTT is used to treat a variety of carcinomas, including acute lymphoblastic leukaemia, head and neck cancer, gastric cancer, breast cancer and choriocarcinoma. Experimental approach: A nanocomposite made of Fe and Mg linked to a 1,4-benzene dicarboxylate ligand metal organic framework (FeMg-BDC MOF) was created for this investigation. Using field emission scanning electron microscopy, the morphology and structure of the Mg-BDC MOF were examined. Next, a screen-printed electrode modified with a synthetic nanocomposite (FeMg-BDC MOF/SPE) was used as the working electrode for voltammetric detection of CFT. Key results: The FeMg-BDC MOF/SPE demonstrated high electrocatalytic activity for CFT oxidation as compared to unmodified SPE. The limit of detection is 0.04 μM, and under ideal conditions, the oxidation peak currents of CFT show a linear relationship with its concentration in the range of 0.1 to 390.0 μM. Additionally, when MTT was present, the FeMg-BDC MOF/SPE demonstrated good activity toward CFT determination. The separation of the oxidation peak potentials (255 mV) indicates that differential pulse voltammetry can be used to detect these two medications simultaneously. Conclusion: The devised sensor's applicability was confirmed with outstanding results using CFT and MTT assays in pharmaceutical specimens and urine samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.